MedTrace Logo

Phase Ib/II Platform Study of Multiple Anti-Cancer Agents in Participants With Metastatic Prostate Cancer

NCT07590934 · Status: NOT_YET_RECRUITING · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 152

Last updated 2026-05-15

No results posted yet for this study

Summary

The purpose of the study is to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary efficacy of multiple anti-cancer agents in participants with metastatic prostate cancer.

Conditions

Interventions

DRUG

AZD2265 (FPI-2265)

AZD2265 (FPI-2265) will be administered as an intravenous (IV) injection.

DRUG

AZD9574

AZD9574 will be administered orally.

DRUG

Docetaxel

Docetaxel will be administered as an IV infusion.

DRUG

AZD2287 (Imaging agent)

AZD2287 will be administered as an IV injection.

Sponsors & Collaborators

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-05-14
Primary Completion
2029-09-05
Completion
2029-09-05
FDA Drug
Yes

Countries

  • United States
  • Australia
  • Germany
  • Italy
  • South Korea
  • Spain
  • United Kingdom

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07590934 on ClinicalTrials.gov